Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Male circumcision and herpes simplex virus type 2 infection in female partners: a randomized trial in Rakai, Uganda.
Tobian AA, Kigozi G, Redd AD, Serwadda D, Kong X, Oliver A, Nalugoda F, Quinn TC, Gray RH, Wawer MJ.
J Infect Dis. 2012 Feb;205(3):486-90. Epub 2011 Dec 5.
Related citations
C21orf91 genotypes correlate with herpes simplex labialis (cold sore) frequency: description of a cold sore susceptibility gene.
Kriesel JD, Jones BB, Matsunami N, Patel MK, St Pierre CA, Kurt-Jones EA, Finberg RW, Leppert M, Hobbs MR.
J Infect Dis. 2011 Dec;204(11):1654-62.
The first common cold sore susceptibility gene.
Cunningham AL, Booth D.
J Infect Dis. 2011 Dec;204(11):1645-7. No abstract available.
Time to refocus on HSV interventions for HIV prevention?
Tanton C, Abu-Raddad LJ, Weiss HA.
J Infect Dis. 2011 Dec 15;204(12):1822-6. Epub 2011 Oct 12. No abstract available.
High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C.
J Infect Dis. 2011 Dec 15;204(12):1912-7. Epub 2011 Oct 12.
The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions.
Schiffer JT, Wald A, Selke S, Corey L, Magaret A.
J Infect Dis. 2011 Aug 15;204(4):554-61.
Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006.
Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE.
J Infect Dis. 2011 Aug 15;204(4):566-73.
Viral kinetics of genital herpes: a molecular probe into host-viral interactions.
Quinn TC.
J Infect Dis. 2011 Aug 15;204(4):495-8. No abstract available.
Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa.
Dudek TE, Torres-Lopez E, Crumpacker C, Knipe DM.
J Infect Dis. 2011 May 15;203(10):1434-41. Epub 2011 Apr 14. Erratum in: J Infect Dis. 2011 Aug;204(3):492.
Effects of HIV-1 and herpes simplex virus type 2 infection on lymphocyte and dendritic cell density in adult foreskins from Rakai, Uganda.
Johnson KE, Redd AD, Quinn TC, Collinson-Streng AN, Cornish T, Kong X, Sharma R, Tobian AA, Tsai B, Sherman ME, Kigozi G, Serwadda D, Wawer MJ, Gray RH.
J Infect Dis. 2011 Mar 1;203(5):602-9. Epub 2011 Jan 10.
Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N, Sanchez J, Essex M, Makhema J, Kiarie J, Farquhar C, Corey L.
J Infect Dis. 2011 Jan 1;203(1):117-21.
Persistent genital herpes simplex virus-2 shedding years following the first clinical episode.
Phipps W, Saracino M, Magaret A, Selke S, Remington M, Huang ML, Warren T, Casper C, Corey L, Wald A.
J Infect Dis. 2011 Jan 15;203(2):180-7. Epub 2010 Dec 9.
Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies.
Quenelle DC, Lampert B, Collins DJ, Rice TL, Painter GR, Kern ER.
J Infect Dis. 2010 Nov 15;202(10):1492-9. Epub 2010 Oct 5.
Asymptomatic herpes simplex virus type 2 shedding-potential pitfalls of broader testing and aggressive suppression.
Tarchini G.
J Infect Dis. 2010 Sep 15;202(6):979; author reply 979-80. No abstract available.
Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
Kim HN, Wang J, Hughes J, Coombs R, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Fuchs J, Eshleman SH, Khaki L, McMahon MA, Siliciano RF, Wald A, Celum C.
J Infect Dis. 2010 Sep 1;202(5):734-8.
Adherence in HIV type 1 prevention trials.
Baeten JM.
J Infect Dis. 2010 May 1;201(9):1279-81. No abstract available.
Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.
Tanton C, Weiss HA, Rusizoka M, Legoff J, Changalucha J, Baisley K, Mugeye K, Everett D, Belec L, Clayton TC, Ross DA, Hayes RJ, Watson-Jones D.
J Infect Dis. 2010 May 1;201(9):1285-97.
Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.
Fuchs J, Celum C, Wang J, Hughes J, Sanchez J, Cowan F, Reid S, Delany-Moretlwe S, Corey L, Wald A; HIV Prevention Trials Network 039 Protocol Team.
J Infect Dis. 2010 Apr 15;201(8):1164-8.
An evolving understanding of genital herpes pathogenesis: is it time for our approach to therapy to change as well?
Hook EW 3rd.
J Infect Dis. 2010 Feb 15;201(4):486-7. No abstract available.
Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa.
Tata S, Johnston C, Huang ML, Selke S, Magaret A, Corey L, Wald A.
J Infect Dis. 2010 Feb 15;201(4):499-504.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on